[MOL] Fwd: Update on Angiogenesis/Endostatin Trials [02561] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Fwd: Update on Angiogenesis/Endostatin Trials



In a message dated 11/19/98 10:00:20 AM Eastern Standard Time,
fitecancer@earthlink.net writes:

<< My Dear Friends,
 
 I still have not been able to log onto the various cancer discussion
 groups, so hope you will post the following message to the groups for
 me, if you haven't been alerted to the following message. I hope it will
 provide much hope as it is this HOPE and answer to one of the means to
 beating this disease that we have been praying for. I am encouraged and
 ramain steadfast and determined to learn more, to be educated and to
 pass on the most vital of information to all, so that one day we can be
 healed and cured.  I will resubscribe, Friday. Stay well and 
 
 God Bless
 marty auslander
 
 Subject: Re: [ANGIOGEN] Judah Folkman
 Date: Sat, Nov 14, 1998, 11:11 AM
 
 
 Hello all,
 
 I am a scientist at a major biotech company working on various aspects
 of cancer biology and treatment, including regulation of angiogenesis.
 It is true that a number of laboratories have been unable to reproduce
 the angiostatin and endostatin data published by Dr. Folkman's lab.
 However, one should keep in mind that the general concept of treating
 solid cancers by the ablation of tumor neovascularization remains
 scientifically sound and holds much promise for the development of new
 anti-cancer therapies. The discovery of molecular mechanisms that govern
 the formation and survival of capillaries offers many potential ways to
 control their integrity in developing tumors, which is central to tumor
 progression and metastasis. Not all of the many current studies have
 been as widely publicized as those conducted in the Folkman lab.
 However, the results appear quite impressive, and several
 anti-angiogenesis compounds are now going through clinical
 trials. I would like to suggest that the audience should not overvalue
 the opinion of the Wall Street on the subject. After all, much of it is
 focused on the commercial potential of Entremed, the company that has
 attempted to develop both angiostatin and endostatin, and not on the
 potential of anti-angiogenic agents to become efficient cancer
 therapies, and the potential is definitely there and is very much worth
 exploring in depth. >>


---- Begin included message ----
My Dear Friends,

I still have not been able to log onto the various cancer discussion
groups, so hope you will post the following message to the groups for
me, if you haven't been alerted to the following message. I hope it will
provide much hope as it is this HOPE and answer to one of the means to
beating this disease that we have been praying for. I am encouraged and
ramain steadfast and determined to learn more, to be educated and to
pass on the most vital of information to all, so that one day we can be
healed and cured.  I will resubscribe, Friday. Stay well and 

God Bless
marty auslander

Subject: Re: [ANGIOGEN] Judah Folkman
Date: Sat, Nov 14, 1998, 11:11 AM


Hello all,

I am a scientist at a major biotech company working on various aspects
of cancer biology and treatment, including regulation of angiogenesis.
It is true that a number of laboratories have been unable to reproduce
the angiostatin and endostatin data published by Dr. Folkman's lab.
However, one should keep in mind that the general concept of treating
solid cancers by the ablation of tumor neovascularization remains
scientifically sound and holds much promise for the development of new
anti-cancer therapies. The discovery of molecular mechanisms that govern
the formation and survival of capillaries offers many potential ways to
control their integrity in developing tumors, which is central to tumor
progression and metastasis. Not all of the many current studies have
been as widely publicized as those conducted in the Folkman lab.
However, the results appear quite impressive, and several
anti-angiogenesis compounds are now going through clinical
trials. I would like to suggest that the audience should not overvalue
the opinion of the Wall Street on the subject. After all, much of it is
focused on the commercial potential of Entremed, the company that has
attempted to develop both angiostatin and endostatin, and not on the
potential of anti-angiogenic agents to become efficient cancer
therapies, and the potential is definitely there and is very much worth
exploring in depth.
----------
---- End included message ----